JPWO2022073062A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022073062A5 JPWO2022073062A5 JP2023521190A JP2023521190A JPWO2022073062A5 JP WO2022073062 A5 JPWO2022073062 A5 JP WO2022073062A5 JP 2023521190 A JP2023521190 A JP 2023521190A JP 2023521190 A JP2023521190 A JP 2023521190A JP WO2022073062 A5 JPWO2022073062 A5 JP WO2022073062A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antigen
- amino acid
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 24
- 108091000831 antigen binding proteins Proteins 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 108020001507 fusion proteins Proteins 0.000 claims 12
- 102000037865 fusion proteins Human genes 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 210000004443 dendritic cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000002243 precursor Substances 0.000 claims 4
- 102100039521 C-type lectin domain family 9 member A Human genes 0.000 claims 3
- 101000888548 Homo sapiens C-type lectin domain family 9 member A Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 241001678559 COVID-19 virus Species 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020903586 | 2020-10-05 | ||
| AU2020903586A AU2020903586A0 (en) | 2020-10-05 | Clec9A antibodies | |
| PCT/AU2021/051160 WO2022073062A1 (en) | 2020-10-05 | 2021-10-05 | Clec9a antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544614A JP2023544614A (ja) | 2023-10-24 |
| JP2023544614A5 JP2023544614A5 (https=) | 2024-10-18 |
| JPWO2022073062A5 true JPWO2022073062A5 (https=) | 2024-10-18 |
Family
ID=81127084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521190A Pending JP2023544614A (ja) | 2020-10-05 | 2021-10-05 | Ｃｌｅｃ９ａ抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230374142A1 (https=) |
| EP (1) | EP4225795A4 (https=) |
| JP (1) | JP2023544614A (https=) |
| CN (1) | CN116547003A (https=) |
| AU (1) | AU2021356294A1 (https=) |
| WO (1) | WO2022073062A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026660A1 (en) * | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| US20110110861A1 (en) * | 2008-05-13 | 2011-05-12 | Mireille Hanna Lahoud | Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells |
| CA3049842A1 (en) * | 2017-02-02 | 2018-08-09 | Silverback Therapeutics, Inc. | Construct-peptide compositions and methods of use thereof |
| KR20220007584A (ko) * | 2019-02-11 | 2022-01-18 | 주무토르 바이오로직스 인코포레이티드 | 항-clec2d 항체 및 이의 사용 방법 |
| CN120590542A (zh) * | 2019-03-28 | 2025-09-05 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
-
2021
- 2021-10-05 EP EP21876755.6A patent/EP4225795A4/en active Pending
- 2021-10-05 JP JP2023521190A patent/JP2023544614A/ja active Pending
- 2021-10-05 US US18/029,954 patent/US20230374142A1/en active Pending
- 2021-10-05 CN CN202180081478.XA patent/CN116547003A/zh active Pending
- 2021-10-05 WO PCT/AU2021/051160 patent/WO2022073062A1/en not_active Ceased
- 2021-10-05 AU AU2021356294A patent/AU2021356294A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6862435B2 (ja) | 抗ｗｔ１／ｈｌａ特異的抗体 | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP2024050548A (ja) | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 | |
| CN107405397B (zh) | 抗tim-3抗体 | |
| US12247075B2 (en) | BTN3A binding proteins and uses thereof | |
| JP2021503455A5 (https=) | ||
| JP6421371B2 (ja) | トランスポーターに対する抗体およびその用途 | |
| JP2024001073A5 (https=) | ||
| JP7830445B2 (ja) | インターロイキン１アルファに特異的な真のヒト抗体 | |
| CN106243223B (zh) | 抗人pdl1抗体及其用途 | |
| JP2024509557A (ja) | ＮＫｐ４６に対する抗体とその応用 | |
| JP2022513437A5 (https=) | ||
| JP2018531625A5 (https=) | ||
| JPWO2022114163A5 (https=) | ||
| JP7641292B2 (ja) | 抗ｃｄ１９抗体、その使用方法及び製造方法 | |
| JPWO2022073062A5 (https=) | ||
| JPWO2021068841A5 (https=) | ||
| JP7851923B2 (ja) | インターロイキン１アルファに特異的な真のヒト抗体 | |
| EP4183800A1 (en) | Novel sars-cov-2 neutralizing antibodies | |
| JPWO2023153471A5 (https=) | ||
| JP2011024537A (ja) | トランスポーターに対する抗体およびその用途 | |
| JP2021516989A5 (https=) | ||
| HK40112840A (zh) | 抗cd19抗体及其使用和制备方法 | |
| HK40113078A (zh) | 抗cd19抗体及其使用和制备方法 | |
| JPWO2023154730A5 (https=) |